Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • HER2-positive

    Tag: her2 positive

    You Searched For "HER2-positive"
    AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise

    AstraZeneca, Daiichi Sankyo breast cancer drug Trastuzumab Deruxtecan shows promise

    Medical Dialogues Bureau10 May 2019 9:00 AM IST
    The treatment Trastuzumab Deruxtecan, or DS-8201, demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic...
    Hetero launches generic Lapatinib under the brand name HERTAB in India

    Hetero launches generic Lapatinib under the brand name HERTAB in India

    Farhat Nasim12 Jan 2019 12:14 PM IST
    HERTAB (Lapatinib) is an oral therapy indicated for the treatment of postmenopausal women with HER2-positive advanced breast cancer patients whose...
    EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars

    EMA accepts marketing authorization applications of Mylan and Biocon for 2 biosimilars

    Ruby Khatun Khatun2 Dec 2017 10:00 AM IST
    HERTFORDSHIRE, England, PITTSBURGH and BENGALURU: Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency (EMA) has accepted for...
    Roche Perjeta regimen gets FDA priority review in breast cancer

    Roche Perjeta regimen gets FDA priority review in breast cancer

    Ruby Khatun Khatun4 Oct 2017 9:20 AM IST
    ZURICH: The U.S. Food and Drug Administration (FDA) has granted a priority review for Roche's Perjeta in combination with Herceptin and chemotherapy...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok